BTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1.5
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $2 to $1.5.
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $2 to $1.5.